Jim Simons
UNCY icon

Jim Simons’s Unicycive Therapeutics UNCY Stock Holding History

Jim Simons’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Buy
+24,400
New +$160K ﹤0.01% 2954
2025
Q3 		– Sell
-11,790
Closed -$56.2K – 3947
2025
Q2 		$56.2K Buy
+11,790
New +$72.9K ﹤0.01% 3379
2024
Q3 		– Sell
-3,320
Closed -$16.6K – 3904
2024
Q2 		$16.6K Sell
3,320
-5,966
-64% -$58.7K ﹤0.01% 3399
2024
Q1 		$128K Buy
9,286
+5,877
+172% +$71.3K ﹤0.01% 3326
2023
Q4 		$30K Buy
+3,409
New +$22.3K ﹤0.01% 3534
2022
Q4 		– Sell
-1,290
Closed -$8K – 4430
2022
Q3 		$8K Buy
1,290
+190
+17% +$1.39K ﹤0.01% 3958
2022
Q2 		$9K Buy
+1,100
New +$10.5K ﹤0.01% 4161

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jim Simons's UNCY Position: Q1 2026 in Review

Jim Simons opened a new position in Unicycive Therapeutics (UNCY) in Q1 2026: 24,400 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings. This is a return to the name: Jim Simons previously reported a position in UNCY as recently as Q2 2025.

Jim Simons first reported a position in UNCY in Q2 2022 and has held it in 7 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Jim Simons held 24,400 shares of Unicycive Therapeutics worth $161K as of Q1 2026.
  • Unicycive Therapeutics was a new Jim Simons position in Q1 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2954 holding.
  • Jim Simons first reported a position in Unicycive Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.